Optical correction

Abstract

The present disclosure describes compositions which improve visual acuity and to methods for their use.

1 . A medicament for topical administration to an eye comprising:
 a first active agent comprising a parasympathetic agonist, and   a second active agent selected from the group consisting of a sympathetic antagonist, a sympathetic agonist and combinations thereof.   
   
   
       2 . The medicament of  claim 1  wherein the medicament comprises a form selected from the group consisting of a liquid, a gel, an ointment, and combinations thereof. 
   
   
       3 . The medicament of  claim 1  wherein the parasympathetic agonist acts on acetylcholine receptors. 
   
   
       4 . The medicament of  claim 1  wherein the parasympathetic agonist comprises pilocarpine. 
   
   
       5 . The medicament of  claim 4  wherein the pilocarpine represents from about 0.05 to about 4%. 
   
   
       6 . The medicament of  claim 1  wherein the sympathetic antagonist acts on a-receptors. 
   
   
       7 . The medicament of  claim 1  wherein the sympathetic antagonist is selected from the group consisting of dapiprazole, thymoxamine, and combinations thereof. 
   
   
       8 . The medicament of  claim 1  wherein the sympathetic antagonist comprises dapiprazole 
   
   
       9 . The medicament of  claim 8  wherein the dapiprazole represents from about 0.05 to about 4%. 
   
   
       10 . The medicament of  claim 1  wherein the sympathetic antagonist comprises thymoxamine. 
   
   
       11 . The medicament of  claim 10  wherein the thymoxamine represents from about 0.05 to about 4%. 
   
   
       12 . The medicament of  claim 1  wherein the sympathetic agonist is selected from the group consisting of brimonidine, iopidine, and combinations thereof. 
   
   
       13 . The medicament of  claim 1  wherein the sympathetic antagonist comprises brimonidine. 
   
   
       14 . The medicament of  claim 13  wherein the brimonidine represents from about 0.01 to about 4%. 
   
   
       15 . The medicament of  claim 1  wherein the sympathetic antagonist comprises iopidne. 
   
   
       16 . A method for improving visual acuity comprising:
 administering a first active agent comprising a parasympathetic agonist to an eye, and   administering a second active agent selected from the group consisting of a sympathetic antagonist, a sympathetic agonist, and combinations thereof.   
   
   
       17 . The method of  claim 16  wherein the parasympathetic agonist comprises pilocarpine. 
   
   
       18 . The method of  claim 16  wherein the sympathetic antagonist is selected from the group consisting of dapiprazole, thymoxamine, and combinations thereof. 
   
   
       19 . The method of  claim 16  wherein the sympathetic agonist is selected from the group consisting of brimonidine, iopidine, and combinations thereof. 
   
   
       20 . A method of improving visual acuity comprising:
 administering a single composition comprising a first active agent and a second active agent to an eye, wherein the first and second active agents are selected from the group consisting of a parasympathetic agonist, sympathetic antagonist, a sympathetic agonist, and combinations thereof.   
   
   
       21 . The method of  claim 20  wherein the parasympathetic agonist comprises pilocarpine. 
   
   
       22 . The method of  claim 20  wherein the sympathetic antagonist is selected from the group consisting of dapiprazole, thymoxamine, and combinations thereof. 
   
   
       23 . The method of  claim 20  wherein the sympathetic agonist is selected from the group consisting of brimonidine, iopidine, and combinations thereof. 
   
   
       24 . A method for treating an eye disorder comprising:
 administering a first active agent comprising a parasympathetic agonist to an eye, and   administering a second active agent selected from the group consisting of a sympathetic antagonist, a sympathetic agonist, and combinations thereof.   
   
   
       25 . The method of  claim 24  wherein the eye disorder is selected from the group consisting of presbyopia, myopia, hypermetropia, astigmatism, and combinations thereof. 
   
   
       26 . The method of  claim 24  wherein the parasympathetic agonist comprises pilocarpine. 
   
   
       27 . The method of  claim 24  wherein the sympathetic antagonist is selected from the group consisting of dapiprazole, thymoxamine, and combinations thereof. 
   
   
       28 . The method of  claim 24  wherein the sympathetic agonist is selected from the group consisting of brimonidine, iopidine, and combinations thereof. 
   
   
       29 . A method for treating an eye disorder comprising:
 administering a single composition comprising a first active agent and a second active agent to an eye, wherein the first and second active agents are selected from the group consisting of a parasympathetic agonist, sympathetic antagonist, a sympathetic agonist, and combinations thereof   
   
   
       30 . The method of  claim 29  wherein the eye disorder is selected from the group consisting of presbyopia, myopia, hypermetropia, astigmatism, and combinations thereof. 
   
   
       31 . The method of  claim 30  wherein the parasympathetic agonist comprises pilocarpine. 
   
   
       32 . The method of  claim 30  wherein the sympathetic antagonist is selected from the group consisting of dapiprazole, thymoxamine, and combinations thereof. 
   
   
       33 . The method of  claim 30  wherein the sympathetic agonist is selected from the group consisting of brimonidine, iopidine, and combinations thereof.